Radiochemotherapy in Elderly Patients With Oesophagus Cancer

Phase II of Radiochemotherapy in Elderly Patients With Oesophagus Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02879227

Acronym

Chronos

Enrollment

Registered

2016-08-25

Start date

2010-01-31

Completion date

2014-12-31

Last updated

2016-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagus Cancer

Brief summary

Phase II study of radiochemotherapy for elderly patients with oesophagus cancer.

Detailed description

Phase II study of radiochemotherapy for elderly patients with oesophagus cancer with Radiotherapy = 50 Gy, 2Gy/f ans chemotherapy with 2 arms arm Cisplatin = Cisplatin 75mg/m2 J1J22 or arm Oxaliplatine = oxaliplatine 85mg/m2 every 2 weeks.

Interventions

DRUGCisplatin

Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f

DRUGOxaliplatin

85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

75 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients aged 75 or more with oesophagus cancer (squamous or adenocarcinoma), fit to treat

Exclusion criteria

* previous radiotherapy * no fit to treat

Design outcomes

Primary

Measure	Time frame	Description
Feasibility of treatment: Number of patients with completed treatment	6 weeks after end of the radiochemotherapy	number of patient with completed treatment

Secondary

Measure	Time frame	Description
Tumoral response	6 weeks after end of the radiochemotherapy	tumoral evaluation at 6 weeks after the treatment
Quality of life	6 weeks after end of the radiochemotherapy	QLQC30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026